Stock Research: Dr. Lal PathLabs

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Dr. Lal PathLabs

BSE:539524 INE600L01024
55
  • Value
    66
  • Growth
    75
  • Safety
    Safety
    13
  • Combined
    62
  • Sentiment
    47
  • 360° View
    360° View
    55
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The company offers a range of diagnostic services including core testing, patient diagnosis, prevention, monitoring, and treatment of various diseases, with tests such as Pregnancy Test, Full Body Checkups, Covid 19 Test, and more. It operates throughout India. In the last fiscal year, the company had a market cap of $2902 millions, profits of $229 millions, revenue of $288 millions, and 4980 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 55 (better than 55% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dr. Lal PathLabs are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Dr. Lal PathLabs. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 75% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 66 which means that the company has a financing structure that is safer than 66% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 13 which means that the share price of Dr. Lal PathLabs is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 87% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 47, which means that professional investors are more pessimistic about the stock than for 53% of alternative investment opportunities. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
13 9 1 1
Growth
75 53 83 91
Safety
Safety
66 61 50 56
Sentiment
47 13 37 6
360° View
360° View
55 12 27 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
31 29 3 7
Opinions Change
93 28 50 32
Pro Holdings
n/a 53 77 56
Market Pulse
26 24 65 41
Sentiment
47 13 37 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
13 9 1 1
Growth
75 53 83 91
Safety Safety
66 61 50 56
Combined
62 22 42 46
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
16 17 7 1
Price vs. Earnings (P/E)
10 11 7 1
Price vs. Book (P/B)
9 10 10 1
Dividend Yield
38 42 26 23
Value
13 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
73 65 62 45
Profit Growth
35 52 75 70
Capital Growth
82 32 90 81
Stock Returns
69 65 33 91
Growth
75 53 83 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
69 56 50 72
Refinancing
36 31 27 27
Liquidity
67 63 53 59
Safety Safety
66 61 50 56

Similar Stocks

Discover high‑ranked alternatives to Dr. Lal PathLabs and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.